{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T15:38:41Z","timestamp":1764603521740},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,7,26]],"date-time":"2018-07-26T00:00:00Z","timestamp":1532563200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2018,7,26]],"date-time":"2018-07-26T00:00:00Z","timestamp":1532563200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1007\/s13555-018-0253-2","type":"journal-article","created":{"date-parts":[[2018,7,26]],"date-time":"2018-07-26T14:42:16Z","timestamp":1532616136000},"page":"495-501","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Topical Application of 5-Fluorouracil Associated with Distant Seborrheic Dermatitis-like Eruption: Case Report and Review of Seborrheic Dermatitis Cutaneous Reactions after Systemic or Topical Treatment with 5-Fluorouracil"],"prefix":"10.1007","volume":"8","author":[{"given":"Tyler","family":"Werbel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip R.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,7,26]]},"reference":[{"issue":"5","key":"253_CR1","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/nrc1074","volume":"3","author":"DB Longley","year":"2003","unstructured":"Longley DB, Harkin DP, Johnston PG. 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003;3(5):330\u20138.","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"253_CR2","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/S0733-8635(03)00028-7","volume":"21","author":"AK Gupta","year":"2003","unstructured":"Gupta AK, Bluhm R, Cooper EA, Summerbell RC, Batra R. Seborrheic dermatitis. Dermatol Clin. 2003;21(3):401\u201312.","journal-title":"Dermatol Clin"},{"issue":"9","key":"253_CR3","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.2217\/pgs.11.72","volume":"12","author":"U Amstutz","year":"2011","unstructured":"Amstutz U, Froehlich TK, Largiad\u00e8r CR. Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity. Pharmacogenomics. 2011;12(9):1321\u201336.","journal-title":"Pharmacogenomics."},{"issue":"16","key":"253_CR4","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1016\/S1470-2045(15)00286-7","volume":"16","author":"D Meulendijks","year":"2015","unstructured":"Meulendijks D, Henricks LM, Sonke GS, et al. Clinical relevance of DPYD variants c.1679T\u2009>\u2009G, c.1236G\u2009>\u2009A\/HapB3, and c.1601G\u2009>\u2009A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data. Lancet Oncol. 2015;16(16):1639\u201350.","journal-title":"Lancet Oncol."},{"key":"253_CR5","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1002\/1097-0142(196101\/02)14:1<131::AID-CNCR2820140118>3.0.CO;2-3","volume":"14","author":"VK Vaitkevicius","year":"1961","unstructured":"Vaitkevicius VK, Brennan MJ, Beckett VL, Kelly JE, Talley RW. Clinical evaluation of cancer chemotherapy with 5-fluorouracil. Cancer. 1961;14:131\u201352.","journal-title":"Cancer"},{"key":"253_CR6","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1111\/j.1365-2133.1962.tb13497.x","volume":"74","author":"G Falkson","year":"1962","unstructured":"Falkson G, Schulz EJ. Skin changes in patients treated with 5-fluorouracil. Br J Dermatol. 1962;74:229\u201336.","journal-title":"Br J Dermatol"},{"issue":"1","key":"253_CR7","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1001\/jama.1969.03160010146027","volume":"208","author":"EF Omura","year":"1969","unstructured":"Omura EF, Torre D. Inflammation of actinic keratoses due to systemic fluorouracil therapy. JAMA. 1969;208(1):150\u20131.","journal-title":"JAMA"},{"issue":"6","key":"253_CR8","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1038\/clpt.2013.172","volume":"94","author":"KE Caudle","year":"2013","unstructured":"Caudle KE, Thorn CF, Klein TE, et al. Clinical pharmacogenetics implementation consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing. Clin Pharmacol Ther. 2013;94(6):640\u20135.","journal-title":"Clin Pharmacol Ther"},{"key":"253_CR9","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1001\/archderm.1963.01590210005001","volume":"88","author":"CJ Dillaha","year":"1963","unstructured":"Dillaha CJ, Jansen GT, Honeycutt WM, Bradford AC. Selective cytotoxic effect of topical 5-fluorouracil. Arch Dermatol. 1963;88:247\u201356.","journal-title":"Arch Dermatol"},{"issue":"6","key":"253_CR10","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/S0190-9622(81)80196-X","volume":"4","author":"DK Goette","year":"1981","unstructured":"Goette DK. Topical chemotherapy with 5-fluorouracil. A review. J Am Acad Dermatol. 1981;4(6):633\u201349.","journal-title":"J Am Acad Dermatol."},{"key":"253_CR11","doi-asserted-by":"crossref","unstructured":"Cohen PR. Topical application of 5-fluorouracil 5 percent cream associated with severe neutropenia: discussion of a case and review of systemic reactions after topical treatment with 5-fluorouracil. Dermatol Online J. 2018;24(4).","DOI":"10.5070\/D3244039360"},{"issue":"1","key":"253_CR12","first-page":"7","volume":"4","author":"JA Dong","year":"1996","unstructured":"Dong JA, Brodell RT. Exacerbation of seborrheic dermatitis following topical 5-fluorouracil. J Geriatr Dermatol. 1996;4(1):7\u201310.","journal-title":"J Geriatr Dermatol."},{"issue":"2","key":"253_CR13","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1001\/archdermatol.2010.420","volume":"147","author":"EE Brodell","year":"2011","unstructured":"Brodell EE, Smith E, Brodell RT. Exacerbation of seborrheic dermatitis by topical fluorouracil. Arch Dermatol. 2011;147(2):245\u20136.","journal-title":"Arch Dermatol"},{"key":"253_CR14","doi-asserted-by":"crossref","unstructured":"Haddock ES, Cohen PR. 5-Fluorouracil-induced exacerbation of rosacea. Dermatol Online J. 2016;22(11).","DOI":"10.5070\/D32211033164"},{"issue":"5","key":"253_CR15","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1111\/j.1365-4362.1989.tb01366.x","volume":"28","author":"SJ Vukelja","year":"1989","unstructured":"Vukelja SJ, James WD, Weiss RB. Severe dermatologic toxicity from 5-fluorouracil in the presence of seborrheic dermatitis. Int J Dermatol. 1989;28(5):353\u20134.","journal-title":"Int J Dermatol"},{"issue":"1","key":"253_CR16","first-page":"64","volume":"39","author":"K Dudley","year":"1987","unstructured":"Dudley K, Micetich K, Massa MC. Erythema with features of seborrheic dermatitis and lupus erythematosus associated with systemic 5-fluorouracil. Cutis. 1987;39(1):64\u20136.","journal-title":"Cutis"},{"issue":"5","key":"253_CR17","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1001\/archdermatol.2012.125","volume":"148","author":"V Huang","year":"2012","unstructured":"Huang V, Hepper D, Anadkat M, Cornelius L. Cutaneous toxic effects associated with vemurafenib and inhibition of the BRAF pathway. Arch Dermatol. 2012;148(5):628\u201333.","journal-title":"Arch Dermatol"},{"issue":"2","key":"253_CR18","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1634\/theoncologist.2010-0298","volume":"16","author":"C Pinto","year":"2011","unstructured":"Pinto C, Barone CA, Girolomoni G, et al. Management of skin toxicity associated with cetuximab treatment in combination with chemotherapy or radiotherapy. Oncologist. 2011;16(2):228\u201338.","journal-title":"Oncologist."},{"issue":"11","key":"253_CR19","doi-asserted-by":"crossref","first-page":"2","DOI":"10.5070\/D33K04Q19C","volume":"15","author":"S Benomar","year":"2009","unstructured":"Benomar S, Boutayeb S, Afifi Y, et al. Hand-foot syndrome and seborrheic dermatitis-like eruption induced by erlotinib. Dermatol Online J. 2009;15(11):2.","journal-title":"Dermatol Online J"},{"issue":"2","key":"253_CR20","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.jaad.2005.12.016","volume":"55","author":"JE Graves","year":"2006","unstructured":"Graves JE, Jones BF, Lind AC, Heffernan MP. Nonscarring inflammatory alopecia associated with the epidermal growth factor receptor inhibitor gefitinib. J Am Acad Dermatol. 2006;55(2):349\u201353.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"253_CR21","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1111\/j.1540-9740.2005.03961.x","volume":"4","author":"NS Scheinfeld","year":"2005","unstructured":"Scheinfeld NS. Seborrheic dermatitis. Skinmed. 2005;4(1):49\u201350.","journal-title":"Skinmed."},{"issue":"9","key":"253_CR22","doi-asserted-by":"crossref","first-page":"12","DOI":"10.5070\/D392R0M8MG","volume":"16","author":"Y Kawakami","year":"2010","unstructured":"Kawakami Y, Nakamura-Wakatsuki T, Yamamoto T. Seborrheic dermatitis-like eruption following interleukin-2 administration. Dermatol Online J. 2010;16(9):12.","journal-title":"Dermatol Online J"},{"issue":"4","key":"253_CR23","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1067\/mjd.2003.87","volume":"48","author":"VC Hall","year":"2003","unstructured":"Hall VC, El-Azhary RA, Bouwhuis S, Rajkumar SV. Dermatologic side effects of thalidomide in patients with multiple myeloma. J Am Acad Dermatol. 2003;48(4):548\u201352.","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"253_CR24","first-page":"23","volume":"10","author":"RR Riahi","year":"2017","unstructured":"Riahi RR, Cohen PR. Dasatinib-induced seborrheic dermatitis-like eruption. J Clin Aesthet Dermatol. 2017;10(7):23\u20137.","journal-title":"J Clin Aesthet Dermatol."},{"issue":"3","key":"253_CR25","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1111\/j.1365-2133.2007.08357.x","volume":"158","author":"CH Yang","year":"2008","unstructured":"Yang CH, Lin WC, Chuang CK, et al. Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy. Br J Dermatol. 2008;158(3):592\u20136.","journal-title":"Br J Dermatol"},{"issue":"36","key":"253_CR26","doi-asserted-by":"publisher","first-page":"5786","DOI":"10.1200\/JCO.2006.08.6868","volume":"24","author":"KY Tsai","year":"2006","unstructured":"Tsai KY, Yang CH, Kuo TT, Hong HS, Chang JW. Hand-foot syndrome and seborrheic dermatitis-like rash induced by sunitinib in a patient with advanced renal cell carcinoma. J Clin Oncol. 2006;24(36):5786\u20138.","journal-title":"J Clin Oncol"},{"issue":"2","key":"253_CR27","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","volume":"30","author":"CA Naranjo","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239\u201345.","journal-title":"Clin Pharmacol Ther"},{"issue":"5 Pt 2","key":"253_CR28","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/S0190-9622(88)70252-2","volume":"19","author":"WB Shelley","year":"1988","unstructured":"Shelley WB, Shelley ED. Scrotal dermatitis caused by 5-fluorouracil (Efudex). J Am Acad Dermatol. 1988;19(5 Pt 2):929\u201331.","journal-title":"J Am Acad Dermatol"},{"issue":"18","key":"253_CR29","first-page":"2772","volume":"18","author":"XQ Liu","year":"2014","unstructured":"Liu XQ, Zhuang M, Wang Z, Huber RM. Correlation between dihydropyrimidine dehydrogenase and efficacy and toxicity of fluoropyrimidine drugs. Eur Rev Med Pharmacol Sci. 2014;18(18):2772\u20136.","journal-title":"Eur Rev Med Pharmacol Sci."},{"issue":"2","key":"253_CR30","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1111\/j.1365-2125.2007.02869.x","volume":"64","author":"N Magn\u00e9","year":"2007","unstructured":"Magn\u00e9 N, Etienne-Grimaldi MC, Cals L, et al. Dihydropyrimidine dehydrogenase activity and the IVS14\u2009+\u20091G\u2009>\u2009A mutation in patients developing 5FU-related toxicity. Br J Clin Pharmacol. 2007;64(2):237\u201340.","journal-title":"Br J Clin Pharmacol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-018-0253-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-018-0253-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-018-0253-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T11:29:23Z","timestamp":1724412563000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-018-0253-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,26]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["253"],"URL":"https:\/\/doi.org\/10.1007\/s13555-018-0253-2","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"type":"print","value":"2193-8210"},{"type":"electronic","value":"2190-9172"}],"subject":[],"published":{"date-parts":[[2018,7,26]]},"assertion":[{"value":"20 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2018","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}